Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study

Edwin Hayes; Caroline Derrick; Danielle Smalls; Hilary Smith; Nicole Kremer; Sharon Weissman

doi:10.1093/ofid/ofaa285

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study

Open Forum Infect Dis. 2020 Sep 3;7(9):ofaa285. doi: 10.1093/ofid/ofaa285. eCollection 2020 Sep.

Authors

Edwin Hayes¹, Caroline Derrick², Danielle Smalls³, Hilary Smith³, Nicole Kremer³, Sharon Weissman¹

Affiliations

¹ Palmetto Health - University of South Carolina Immunology Center, Prisma Health, Columbia, South Carolina.
² University of South Carolina College of Pharmacy, Prisma Health, Columbia, South Carolina.
³ University of South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina.

Abstract

Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern US, predominantly African American overweight population, we found optimal virologic control and low discontinuation rates, with 4% discontinuing BIC/FTC/TAF due to rash, low platelets, loss of appetite, and insomnia.

Keywords: adverse events; antiretroviral therapy; bictegravir; drug reaction; rash.